KOLs in breast cancer provide insights on de-escalation of adjuvant anti-HER2 therapy and need for HER2 testing of residual disease after neoadjuvant therapy.
Data from the following clinical trials are discussed:
Three-year follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2-positive breast cancer (TRAIN-2): A randomized phase III trial. (van der Voort A et al. 2020 ASCO annual meeting. Abstract 501.)
Primary analysis of KAITLIN: A phase III study of trastuzumab emtansine (T-DM1) + pertuzumab versus trastuzumab + pertuzumab + taxane, after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer. (Harbeck N et al. 2020 ASCO annual meeting. Abstract 500.)
Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2+ breast cancer: Subgroup analysis from KATHERINE. (Loibl S et al. 2020 ESMO Breast Cancer annual meeting. Abstract 96O.)